Galena Biopharma (NASDAQ:GALE) Earning Somewhat Critical Press Coverage, Accern Reports
Media stories about Galena Biopharma (NASDAQ:GALE) have trended somewhat negative this week, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Galena Biopharma earned a news sentiment score of -0.12 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 92 out of 100, indicating that recent media coverage is extremely likely to have an impact on the company’s share price in the next several days.
A number of research firms have recently issued reports on GALE. ValuEngine downgraded Galena Biopharma from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research downgraded Galena Biopharma from a “buy” rating to a “hold” rating in a research report on Tuesday, May 16th.
Shares of Galena Biopharma (NASDAQ:GALE) opened at 0.581 on Friday. The company’s market cap is $21.75 million. The company’s 50-day moving average price is $0.57 and its 200-day moving average price is $0.97. Galena Biopharma has a 12 month low of $0.52 and a 12 month high of $42.40.
Galena Biopharma (NASDAQ:GALE) last issued its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($0.09) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.13. During the same period in the previous year, the company posted ($0.07) EPS. Equities analysts forecast that Galena Biopharma will post ($0.56) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Galena Biopharma (NASDAQ:GALE) Earning Somewhat Critical Press Coverage, Accern Reports” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/galena-biopharma-nasdaqgale-earning-somewhat-critical-press-coverage-accern-reports/1406755.html.
About Galena Biopharma
Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.
Receive News & Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.